Star Therapeutics is focused on discovering and developing first-in-class antibodies that address significant unmet needs in hematology and related disorders. Its lead candidate, VGA039, targets Protein S to rebalance coagulation and is positioned as a universal therapy for bleeding disorders, beginning with von Willebrand Disease (VWD). VGA039 is currently being evaluated in a pivotal Phase 3 clinical trial in VWD patients. The company plans to leverage the same platform to expand its pipeline to additional bleeding indications. An oversubscribed $125 million Series D round provides the capital to advance VGA039 through late-stage development and to progress other pipeline programs. The strong investor syndicate, which now includes GordonMD Global Investments alongside existing life-sciences backers, signals broad confidence in the company’s scientific approach. Co-lead investors Sanofi Ventures and Viking Global Investors add strategic and financial support to help drive regulatory and commercial milestones. With this new funding, Star Therapeutics is positioned to accelerate clinical development while maintaining its discovery efforts for future antibody candidates.

Total raised

$315M

Funding rounds

3

Latest round

Series D

Latest activity

Oct 2025